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Abstract 
The use of 3-dimensional (3D) collagen gels has yielded new insights into the migratory 
behaviour of cancer cells. While the large GTPase dynamin has emerged as an important 
regulator of cancer cell migration and invasion under 2D conditions, its role in 3D migration 
is unclear. We have used a potent dynamin modulator, a bis-tyrphostin derivative, Ryngo
®
 1-
23, to investigate the role of dynamin in 3D migration in 3 different cell lines. The compound 
specifically inhibits persistent, elongated 3D migration in U87MG and SMA-560 cells. 
Treated U87MG cells adopt a rounded morphology that is not due to apoptosis, loss of matrix 
metalloprotease activity or inhibition of clathrin-mediated endocytosis. Given that Ryngo 1-
23 is known to regulate dynamin oligomerisation and actin dynamics at the leading edge, we 
analyzed actin filament distribution. Ryngo 1-23 induced a switch in actin filament 
organization in 3D cultures resulting in the generation of multiple short actin-rich 
microspikes. Correlated with the change in actin filament distribution, cells displayed 
reduced collagen gel contraction. Since acto-myosin force transmission to the extra-cellular 
matrix underpins persistent, elongated migration, our results suggest that Ryngo 1-23 
modulates this process in 3D migration via dynamin-mediated regulation of acto-myosin 
force transmission to the extra-cellular matrix. 
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1. Introduction 
The progression to invasive, metastatic disease remains a major impediment to the 
successful treatment of cancer. Thus there have been intensive research efforts to identify the 
molecules and mechanisms that underpin the migratory ability of invasive cancer cells. While 
much work has been done using cells grown on planar 2-dimensional (2D) surfaces, it is 
increasingly realized that the 3D tissue structure surrounding cancer cells in vivo is an 
important determinant of cell migration behaviour [1-4]. Therefore the use of 3D culture 
models imparts important physiological insights into cancer cell migration. The large GTPase 
dynamin has emerged as an important regulator of cancer cell invasion [5], but to date the 
role that this protein plays in the negotiation of a 3D tissue architecture is not understood. 
In a 3D matrix cells must generate contractile force through their actin cytoskeleton, 
transmit this force via adhesion to the matrix and then either deform themselves in order to 
squeeze through pores in the matrix, or alternatively, secrete proteases to degrade the matrix 
and thereby create space for the cell body [6]. The greater the adhesion force the cell can 
transmit to the surrounding matrix the faster they can move through the 3D matrix and the 
greater their directional persistence [7]. In the transition zone between the lamellipodia and 
the lamella where focal adhesions form, a molecular clutch has been proposed to form 
between the focal adhesions and the actin filaments [8].  This clutch facilitates acto-myosin 
force transmission to the extra-cellular matrix and thus regulates forward cell movement. 
Cancer cells characteristically adopt different morphologies reflecting their response to the 
constraints imposed by a 3D matrix [1, 2]. The two most commonly described morphologies 
are an elongated/mesenchymal cell shape versus a rounded/amoeboid cell shape. During 
elongated cell migration, cells secrete matrix metalloproteases and pull themselves forward 
by attaching to matrix fibres. In contrast, rounded invasion is considered to be adhesion-
independent and depends on a highly contractile acto-myosin cytoskeleton that produces 
membrane blebs which allow cells to squeeze through pores in the matrix. 
In addition to these well-described 3D invasion behaviours (and other alternative modes 
[9]) we showed that rounding can be induced by elevated expression of the actin accessory 
protein tropomyosin Tm5NM1 [10, 11]. This induces a prominent change in the organization 
of actin filaments in 3D, with cells displaying multiple actin-rich microspikes that align with 
the surrounding matrix fibres. Following elevated Tm5NM1 expression leading to cell 
rounding and microspike formation, cells become non-motile. Thus actin filament 
organization in 3D culture conditions reflects different cellular motility outcomes. 
Functional dynamin GTPase is formed via the association of subunits in a tetramer that 
further organizes into a helical polymer [5]. The tetramer structure facilitates dynamin 
interaction with the neck of clathrin-coated pits during vesicle endocytosis. Dynamin 
oligomers also associate with, and elongate, actin filaments [12, 13].  Correspondingly, many 
studies show that dynamin plays a role in actin cytoskeletal dynamics [5, 14, 15]. Recent 
studies suggest that dynamin 2 may regulate the molecular clutch at the leading edge of 
motile cells [16]. Reducing dynamin function by siRNA-mediated depletion, dominant 
negative dynamin II expression and dynamin chemical inhibitors (dynasore and myristyl 
trimethyl ammonium bromide (MiTMAB™)) all reduce 2D cell migration and transwell 
matrigel invasion [17, 18]. Dynamin also regulates the endocytic delivery of membrane-type 
matrix metalloproteinase 1 to the cell surface, for the conversion of the pro-form of the 
matrix-metalloprotease MMP-2 to active MMP-2 [19] that is important for elongated cell 
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migration in 3D culture. Endocytosis-mediated turnover of focal adhesions to the extra-
cellular matrix and actin filament dynamics are also critical to elongated cell migration and 
are each regulated by dynamin [13, 20, 21]. Finally, dynamin plays a role in the activation of 
Arp2/3 [22] that is required for actin filament branching and membrane extension at the 
leading edge [23]. Collectively, these data suggest that dynamin may play a role in regulating 
elongated 3D migration. 
To study dynamin in cellular functions there is now available an array of small molecules 
targeting different aspects of dynamin function, including Ryngo 1-23 (2-cyano-N-{3-[2-
cyano-3- (3,4,5-trihydroxyphenyl) acryloylamino]propyl}-3-(3,4,5 trihydroxyphenyl) 
acrylamide) (previously named Bis-T-23 [24]). The inhibitory activity of Ryngo 1-23 that 
solely occurs in vitro [24] is contrasted with effects reported in vivo. In cells, Ryngo 1-23 has 
been demonstrated to promote dynamin oligomerization and thus stimulate the basal GTPase 
activity of dynamin [12]. Specifically, Ryngo 1-23 stimulates actin-dependent dynamin 
oligomerization at the cell’s leading edge, in the transition zone between the lamellipodium 
and the lamellae, where the molecular clutch between actin and adhesion is engaged [12]. 
Thus, Ryngo 1-23 is a useful agent for investigating the role of actin-dependent dynamin 
oligomerization in cellular processes [12]. In the present study we have used Ryngo 1-23 to 
investigate the function of dynamin in 3D cell migration.  
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2. Materials and Methods 
2.1 Cell culture, antibodies and reagents 
 
Rat neuroblastoma (B35), human glioblastoma (U87MG), and human fibrosarcoma 
(HT1080) cell lines were maintained in Dulbecco's Modified Eagles Medium (DMEM) 
(Invitrogen) supplemented with 10% Foetal Bovine Serum (FBS). Growth of cells in 3D 
collagen gels and media for live imaging has been previously described [11]. MMP-2 pro- 
and active enzymes (Calbiochem, Merck) were used as positive controls for zymography. 
Stock solution of Ryngo
®
 1-23 [25] and Dynole
®
 34-2 [26] were prepared in DMSO. 
2.2 Live cell imaging, migration analysis and collagen gel contraction 
 
Cells were seeded in 3D collagen gels (1.7 mg/ml) in 24 well plates at a density of 3 x 10
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cells per ml with 500µl of cell/collagen solution per well. Collagen was polymerised for at 
least 1 hour prior to the addition of 1 ml of DMEM containing 10% FBS. Following 
overnight incubation, complete media was exchanged for 500µl of serum-free DMEM 
containing dynamin targeting compounds.  DMSO in all controls and drug-treated wells was 
maintained at 1% v/v. Following incubation at 37ºC for 30 minutes cultures were 
supplemented with an equal volume of CO2-independent media containing 10% FBS for live 
cell imaging. Time-lapse images were captured over a period of 5 hours using an ORCA 
ERG cooled CCD camera (Hamamatsu, SDR Clinical Technology NSW, Australia) and an 
Olympus IX81 inverted microscope (Olympus) equipped with an environmental chamber 
heated to 37ºC. Transmitted light images were captured using a 20X objective. Cells 
undergoing division or apoptosis were excluded from analyses. Nuclear translocation was 
tracked in time-lapse image stacks using Metamorph V6.3 software (Molecular Devices, 
Sunnyvale, CA, USA). Directional persistence was calculated from Mean Squared 
Displacement (MSD) of cells versus time as previously described [6]. Relative cell 
elongation was determined by measuring the longest cell axis at the beginning and at the end 
of time lapse imaging. Quantification of cell viability was performed by direct addition of 
10µM propidium iodide to 3D cell cultures.  Viable cells were identified by exclusion of 
propidium iodide. Analysis of collagen gel contraction was performed as previously 
described [27]. 
2.3 Confocal microscopy 
 
U87MG cells seeded in 3D collagen gels were fixed with 4% paraformaldehyde in phosphate 
buffered saline (PBS) and then stained with fluorescently-tagged phalloidin. Cell nuclei were 
counter-stained with prolong gold containing DAPI (Molecular probes, Invitrogen) and 
examined using a FluoView FV1000 confocal microscope (Olympus, Walkersville, NY, 
USA) with a UPLSAPO 60_NA1.2 water-immersion lens. TRITC-phalloidin was detected 
with a 559 nm laser set at 16.5% and DAPI with a 405 nm laser set at 42%.  Imaging was 
performed with a 10 ms/ pixel sampling speed. Images were captured at 1024x1024 pixel 
resolution at 0.5 µm intervals. Final micrograph images were prepared using Photoshop C2S 
(Adobe, San Jose, CA, USA). 
2.4 MMP-2 zymography 
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Cell supernatants and pro- and active MMP-2 standards (Calbiochem, Darmstadt, Germany) 
were assayed for gelatinase activity using a zymography assay. Briefly, electrophoresis was 
performed on 10% SDS-PAGE containing 1 mg/mL gelatin. Gels were washed in 2.5% (v/v) 
Triton X-100 and incubated overnight at 37°C in enzyme activation buffer (50 mM Tris-HCl, 
200 mM NaCl, 0.02% (v/v) Tween 20 and 5 mM CaCl2, pH 7.3). Gels were stained with 
Coomassie blue solution, destained and MMP-2 activity visualized as clear bands on a dark 
background. 
2.5 Clathrin-mediated endocytosis 
 
Assay of clathrin-mediated endocytosis was performed in a 96-well plate format as described 
previously (Hill et al 2009). Briefly, cells were grown and incubated with the drugs or vehicle 
for 30 min prior to addition of A594-conjugated transferrin (Tfn-A594) for 8 min at 37
o
C.  
Cell surface bound transferrin was removed by a low pH acid wash and the cells were then 
fixed with paraformaldehyde. Tfn uptake was quantitated using an automated acquisition and 
analysis system (ImageXpress Micro (IXM), Molecular Devices, Sunnyvale, CA, USA). The 
average integrated intensity of Tfn-A594 was determined and the data were expressed as 
percentage of control. 
2.6 Statistical analysis 
 
All error bars on graphs represent the standard error of the mean (S.E.M).  Statistical 
comparison of two means was performed by using a Student’s t-test, calculated using Excel 
(Microsoft, Redmond, WA, USA) and comparison of more than two means was performed 
using one-way ANOVA with Tukey’s multiple comparison test, in Prism V4 software 
(GraphPad Software, La Jolla, CA, USA). 
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3. Results 
3.1 Ryngo 1-23 inhibits glioblastoma 3D migration 
 
The selected cell lines were the U87MG glioblastoma, B35 neuroblastoma and HT1080 
fibrosarcoma cells, each of which has been shown to adopt the elongated migration mode in 
3D collagen gels [11, 28]. We first compared the behaviour of each line in 3D culture. B35 
cells extend a thick, leading edge protrusion that displays multiple spikey projections at the 
tip (Figure 1A & Supplementary movie 1). The trailing edge is typically rounded and the cell 
body frequently displays a peanut-shell shape, suggestive of cell body constriction by 
surrounding matrix fibres (Figure 1B arrow heads). The HT1080 cells have previously been 
reported to display a mixed morphology in 3D culture [29] and similarly in our culture 
conditions approximately 50% of HT1080 cells display an elongated phenotype [11]. The 
elongated HT1080 cells move through the gels extending long thin extensions at both the 
leading edge and trailing edges (Figure 1A). Matrix fibres in advance of the leading edge are 
pulled in the direction of the cell, as the cells appear to tug on the collagen fibres (Figure 1C, 
Supplementary movie 2). At the rear a migration track is seen, where the cell has degraded 
and rearranged the matrix as it has created a path (Figure 1C). The U87MG cells also extend 
a long thin leading edge projection, although, in contrast to the HT1080 elongated invasion 
morphology, the U87MG leading edge is frequently a single mono-polar extension and the 
trailing edge is rounded (Figure 1A & supplementary movie 3). Similar to the HT1080 cells, 
the U87MG cells also displace local collagen fibres and in both cell lines it is possible to 
visualize tracks where the matrix has been rearranged as a cell has passed through. The 
U87MG cells move most rapidly through the gel, with an average speed of 0.48 ± 0.03 
m/min, compared with 0.23 ± 0.01 m/min and 0.25 ± 0.01 m/min for the B35 and 
HT1080 cells, respectively. Moreover, not all cells in the population are motile with the 
percentage of motile cells ranging from 60% ± 16 (HT1080), 69% ± 0.9 (U87MG) and 71% 
± 7.3 (B35). Collectively, these data reveal that although each cell line displays an elongated 
mode of invasion, there are differences in their response to the external matrix organization. 
 
We next determined the effect of Ryngo 1-23, a compound that promote dynamin’s 
natural propensity to oligomerise and which stimulates its basal GTPase activity [12], on the 
3D migratory behaviour of each cell line. Analysis of time-lapse series of cells treated with 
increasing concentrations of Ryngo 1-23 revealed that the total percentage of motile cells was 
not significantly affected in either the B35 or HT1080 cells lines, at any concentration tested 
(Figure 2A). In contrast, the percentage of U87MG cells migrating at the highest 
concentration of Ryngo 1-23 tested was significantly reduced (Figure 2A). Moreover, Ryngo 
1-23 caused a concentration-dependent reduction in U87MG 3D migration speed (Figure 2B), 
but not in the B35 or HT1080 cells (Figure 2B). U87MG cells treated with Ryngo 1-23 lost 
their elongated phenotype (Figure 3A). Quantitative analysis confirmed that cell elongation 
was significantly reduced at both 10 and 100 M Ryngo 1-23 concentrations in U87MG cells 
(Figure 3A) but there was no change in the morphology of B35 or HT1080 cells at any 
concentration examined (Supplementary movies 1 and 2). The reduced migration and 
increased rounding in the U87MG cells was not due to apoptosis or changes in proliferation 
in response to Ryngo 1-23, as both apoptotic and mitotic cells were excluded from analyses 
(as determined by cell morphology). Separately, quantification of U87MG cell viability by 
propidium iodide dye exclusion revealed no difference in cell viability at the highest 
concentration of Ryngo 1-23 used in this study (Figure 3B). Notably, the motile Ryngo 1-23-
treated cells use the same elongated migration mode as their control counterparts (Figure 3C 
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and Supplementary Movie 4, note that this movie is for double the length of time as the 
control cell shown in Supplementary Movie 3). In contrast the spherical cells are essentially 
non-motile (Supplementary Movie 5). 
We next asked whether Ryngo 1-23 might also reduce the 3D migration of other 
glioblastoma cells. The SMA-560 mouse glioblastoma cells are similar to the U87MG cells in 
that they invade brain tissue in vivo [30] and are likely to employ similar invasion 
mechanisms. As observed with U87MG cells, the SMA-560 cells displayed a concentration-
dependent reduction in 3D cell speed following treatment with Ryngo 1-23 (Figure 4A). 
Given that the untreated SMA-560 cells had similar speed to the B35 and HT1080 cells (0.2 
± 0.02 m/min) we compared the movement of SMA-560 cells with these lines. Comparison 
of the Mean Squared Displacement (MSD) for each cell line revealed that both the B35 and 
HT1080 curves crossed over the SMA-560 MSD curve, indicating that the SMA-560 cells 
move with increased directional persistence (Figure 4B). This behaviour is emphasized by 
analysis of paths traced by the SMA-560 and B35 cells. While the SMA-560 tended to more 
consistently move in the one direction, the B35 cells frequently changed direction, moving 
back over the same area (Figure 4C). Calculation of the persistence confirmed that the SMA-
560 are significantly more directionally persistent than either the B35 or HT1080 cells 
(Figure 4D). This data indicates that despite the similar overall speed between the B35, 
HT1080 and SMA-560 cells, they employ different strategies to move through the 3D gels. 
Moreover, similar to the U87MG cells, SMA-560 elongation was reduced in the highest 
concentration of Ryngo 1-23 used (Figure 4E). 
3.2 Ryngo 1-23 does not affect MMP activity or clathrin-mediated endocytosis 
 
A switch from elongated to rounded cell morphologies in 3D collagen gels has previously 
been shown to occur in response to the inhibition of matrix metalloprotease (MMP) activity 
[29]. As dynamin regulates the pro-MMP-2 conversion to active MMP via delivery of 
membrane-type MMP-1 to the cell surface [19] and MMP-2 activity is associated with 
glioblastoma migration and invasion [31, 32], we asked whether the rounded phenotype and 
reduced migration speed might reflect Ryngo 1-23 effects on MMP activity. Analysis of 
MMP-2 activity by gelatin zymography revealed that there was no significant difference in 
the amount of secreted pro-MMP-2 in cells treated with Ryngo 1-23 when compared with 
matched controls (Figure 5A and B). Although levels of the active form of MMP-2 were too 
low for accurate quantification by densitometry, in 3 separate experiments faint bands were 
observed and no differences seen between control cell cultures versus cultures exposed to 
Ryngo 1-23 (Figure 5A). Therefore Ryngo 1-23 does not alter U87MG 3D migration via 
inhibition of MMP-2 function. 
Dynamin also mediates clathrin-mediated endocytosis, which is a critical determinant of 
cell migration. Therefore we analyzed Ryngo 1-23 effects on endocytosis in the U87MG 
cells, using brief uptake of fluorescently-labeled transferrin in response to increasing 
concentrations of drug. No significant inhibition was detected, with only ~20% maximal 
inhibition observed at the highest concentration used (Figure 6A). For comparison, we also 
analyzed the effect of Ryngo 1-23 on transferrin uptake in B35 cells and found that Ryngo 1-
23 also did not inhibit endocytosis in these cells (~20% maximal inhibition, Figure 6A). The 
efficacy of the transferrin endocytosis assay was independently confirmed using the well 
characterised dynamin inhibitor Dynole
TM
 34-2 that has previously been shown to inhibit 
clathrin-mediated endocytosis [33]. Dynole 34-2 efficiently inhibited endocytosis in both the 
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U87MG (IC50 of 34.5 ± 10.8 µM) (Figure 6B) and B35 cells (IC50 of 6.6 ± 2.6 µM) (Figure 
6B). Therefore Ryngo 1-23 inhibition of U87MG 3D migration is not due to inhibition of 
endocytosis. 
3.3 Ryngo 1-23 alters glioblastoma adhesion to the matrix 
 
Based on the emerging role for dynamin in regulating the actin cytoskeleton [12], we next 
considered whether the altered cell morphologies in response to Ryngo 1-23 might reflect 
changes in actin filaments. Prominent bundles of filamentous actin were observed at the 
lateral edges of extending membrane processes and in trailing processes in control U87MG 
cells (Figure 7A). In addition, thin, short actin filaments were observed extending into the 
leading edge of the extending membrane process.  In contrast, significantly fewer U87MG 
cells displayed extended protrusions at concentrations of > 10 µM Ryngo 1-23 (Figure 7A). 
Instead, these spheroid-shaped cells frequently displayed actin-rich microspikes emanating 
from all over the cell body (Figure 7A). 3D projections of the phalloidin-stained cells 
emphasizes the differences in actin organization between control cells and cells exposed to 
Ryngo 1-23 (Supplementary movie 6). The actin cytoskeleton is intimately involved in the 
adhesion of the cells to the matrix and the migrating U87MG cells display prominent tugging 
on the matrix fibre. Therefore we asked whether the actin cytoskeleton changes following 
exposure to Ryngo 1-23 might reflect a change in the contractile force exerted by the cells 
through adhesion to the matrix. To test this we performed a collagen contraction assay 
(Figure 7B). This revealed significantly reduced gel contraction at 100 M Ryngo 1-23 
(Figure 7C). Using propidium iodide staining we confirmed that the reduced contractility was 
not due to an increase in apoptosis (Figure 6D). Together this suggests that Ryngo 1-23 
treatment of U87MG reduces the adhesive forces that the cells exert on the surrounding 
matrix. 
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4. Discussion 
Accumulating studies have suggested that dynamin may be an important target for the 
development of anti-invasive therapies for metastatic cancer [17, 18, 34]. Due to the 
increasing understanding of how cancer cells can adopt a range of migratory strategies to 
negotiate complex 3D extra-cellular environments [1] it is critical to use 3D culture methods 
to investigate the efficacy of compounds for blocking cancer cell migration and invasion. The 
results of our study demonstrate that the small molecule dynamin modulator Ryngo 1-23 
suppresses the 3D cell migration speed of the glioblastoma cell lines U87MG and SMA-560. 
Our findings confirm that dynamin indeed plays a role in cell negotiation of a 3D extra-
cellular environment. 
Comparison of the 3D migration behaviours of the B35 neuroblastoma, HT1080 
fibrosarcoma and U87MG cells revealed important differences. Analysis of the B35 cells 
revealed constriction by the local collagen fibres. Similar phenotypes were infrequently seen 
in the HT1080, SMA-560 and U87MG cells. Moreover, while the B35 cells also tugged on 
the fibres ahead of the cell, fibre displacement was much less than that observed with the 
other two cell lines. This suggests a greater adhesion to the surrounding matrix fibres by both 
the HT1080 and U87MG cells. The fact that the U87MG cell speed is almost double that of 
the HT1080 cells further suggests that these cells exert an even greater adhesive force on the 
surrounding fibres than the HT1080 cells.  Previous studies have also revealed differences 
between the behaviour of U87MG and HT1080 cells in 3D collagen [28]. While the SMA-
560 move more slowly than the U87MG cells, the enhanced directional persistence when 
compared with the B35 and HT1080 cells indicates a stronger adhesive force in these cells. 
Since Ryngo 1-23 inhibited 3D migration of U87MG (fast and persistent) and SMA-560 
(persistent) cells, we propose that the compound preferentially inhibits migration that 
depends on strong adhesion to the extra-cellular matrix. 
We tested known dynamin functions to determine whether these functions could account 
for Ryngo 1-23 inhibition of 3D migration and induce rounding. The changes are not due to 
apoptosis, MMP inhibition nor clathrin-mediated endocytosis. It was surprising that Ryngo 1-
23 did not inhibit transferrin uptake, as previous studies have shown Ryngo 1-23 inhibits 
transferrin uptake in dendritic cells [35]. The differences may reflect the bulk endocytosis 
assay based on FACS used in the latter study, rather than the better characterised acute CME 
assay used here.  Cell type specificity may also play a role, given that the dendritic cells are 
professional scavengers. Alternatively, the difference may reflect concentration-specific 
effects. While 100 M Ryngo 1-23 was sufficient to inhibit endocytosis in dendritic cells [35] 
but not in U87MG cells, it is possible that higher concentrations of the compound may inhibit 
U87MG endocytosis. Nonetheless, since significant inhibition of 3D migration speed 
occurred at concentrations as low as 1 µM, inhibition of endocytosis cannot be the cause of 
reduced 3D migration in U87MG cells. Therefore Ryngo 1-23 inhibits U87MG motility by a 
mechanism that is unrelated to dynamin’s function in endocytosis. 
Dynamin plays a role in remodelling actin filaments and thereby influencing global actin 
cytoskeletal structure via either indirect mechanisms including interactions with cortactin 
[36] and regulating the disassembly of focal adhesions that anchor actin filaments [21, 37], or 
directly by interacting with short actin filaments to stimulate their uncapping and elongation 
[13]. Dominant negative dynamin, deficient in the binding and hydrolysis of GTP, is known 
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to alter both cell shape and cytoskeletal structure, causing a redistribution of stress fibres to 
the cell periphery [38]. Further, contractility of the actomyosin cytoskeleton is required for 
cells to exert force through the associated focal adhesions onto the surrounding matrix in 
order to translocate the cell body [39]. Our data reveal that Ryngo 1-23 induces altered actin 
arrangement and a corresponding reduction in the associated adhesive force to the extra-
cellular matrix. Potentially, this reflects reduced ability of the cells to extend new membrane 
in order to form new adhesions to matrix fibres ahead of the cell. Rac GTPase-mediated 
activation of Arp2/3 is critical to the generation of short branched actin filaments that push 
the membrane forward [23]. It is therefore interesting that Rac inhibition differentially affects 
HT1080 versus U87MG cell 3D invasion [28]. While Rac inhibition induces amoeboid 
transition in HT1080 cells, U87MG cells instead display repressed actin polymerization at the 
tips of leading edge membrane protrusions. Our data reveals that Ryngo 1-23 specifically 
inhibits the elongated, directional mode of 3D migration exhibited by the U87MG and SMA-
560 cells. Notably, a recent study using dynamin triple knockout cells revealed that the 
effects of one dynamin inhibitor compound include at least one off-target effect [40].  Thus it 
remains possible that Ryngo 1-23 may be affecting other targets. However, the off-target 
issue is not a problem limited to the use of small molecules as cell biology probes. The 
problem is potentially more significant in genetically manipulated cells where transfections 
and/or knockdowns occur for days instead of minutes, and have many off-target actions on 
other proteins which can be down-regulated [41] or mislocalised in the cell [40].  
Nonetheless, Ryngo 1-23 has been shown to induce actin-dependent dynamin 
oligomerization at the cell’s leading edge [12] and dynamin regulates the actin/adhesion 
molecular clutch at the leading edge [16]. Thus we propose that Ryngo 1-23 modulates the 
actin/adhesion clutch, thus reducing the transmission of the acto-myosin force required for 
elongated, persistent movement in a 3D environment. 
 
Our study has revealed that the dynamin modulating small molecule Ryngo 1-23 
significantly inhibits U87MG and SMA-560 glioblastoma cell 3D migration speed.  
Collectively, our data reveal an important non-endocytic function for dynamin in 3D cell 
migration, but suggests a specific role in the elongated cell invasion that depends on the 
formation of actin stress fibres required to transmit cellular force in order to move through 
the 3D matrix.  
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Legends 
Figure 1. Elongated 3D migration. (A) Bright-field time-lapse images of B35, HT1080 and 
U87MG cells in 3D collagen gels. Time shown in hours and minutes.  Scale bar 50 m. (B) 
B35 cell showing cell body constriction (arrow heads). (C) HT1080 cell showing the 
displacement of collagen fibres at the leading edge (blue lines) and the migration track at the 
trailing edge (green arrow heads). 
Figure 2. Ryngo 1-23 inhibits U87MG 3D migration. (A) Percentage of motile cells in the 
different cell types under the indicated conditions. Graph shows the mean of three 
independent experiments. (B) Average cell speeds. Data show the average of four 
independent experiments, n~30 cells tracked per condition, per experiment.  *p<0.05, 
**p<0.01, ***p<0.001.  
Figure 3. Ryngo 1-23 reduces U87MG elongation. (A) Bright field time-lapse series of 
U87MG cells in 3D collagen gel, time shown in minutes after treatment with Ryngo 1-23. 
Histogram shows elongation ratios (expressed relative to controls) following 5 hours of 
treatment with the indicated concentrations of Ryngo 1-23. Elongation ratios were measured 
by comparing cell length at zero time point to cell length after 5 hours treatment with Ryngo 
1-23. Data are the mean values from three independent experiments. *p<0.05. (B) Viability 
of U87MG cells was unaffected by Ryngo 1-23 exposure as measured by propidium iodide 
dye exclusion following 5 hours treatment with either control DMSO media or 100 µM 
Ryngo 1-23. (C) Motile cells retain an elongated phenotype, but move more slowly through 
the gel. Montage shows U87MG cells treated with 10m Ryngo 1-23. 
Figure 4. Ryngo 1-23 inhibits 3D migration of SMA-560 glioblastoma cells. (A) Average 
SMA-560 cell speeds in the indicated concentrations of Ryngo 1-23. Data show the average 
of four independent experiments, n~30 cells tracked per condition, per experiment. (B) MSD 
calculated from the trajectories of U87MG, SMA-560, B35 and HT1080 cells in 3D collagen 
gels. Data are the average values from at least 4 independent experiments, n=30 cells tracked 
per experiment. (C) Examples of the migration tracks taken by SMA-560 and B35 cells. Each 
time point is indicated by a white spot and the distance travelled between consecutive time 
point is indicated by the joining lines. Shown are examples of 15 individual cells from each 
cell line. (D) B35 and HT1080 cells are significantly less directionally persistent than SMA-
560. (E) Elongation ratios (expressed relative to controls) following 5 hours of treatment with 
the indicated concentrations of Ryngo 1-23. (D) *p<0.05, **p<0.01, ***p<0.0001, NS=not 
significant. 
Figure 5. Cell rounding is not due to inhibited MMP-2 activity. (A) Gelatin zymography of 
MMP-2. Gels were loaded with purified pro-MMP-2 (both the pro- and active forms are 
visible, lane 1) and active MMP-2 (lane 2). MMP-2 levels in conditioned media with 1% 
DMSO and cell-free collagen gels in the absence and presence of 100 µM Ryngo 1-23 are 
shown in lanes 3 and 4, respectively. Lanes 5 and 6 show MMP-2 in conditioned media from 
collagen gels containing U87MG cells in the absence and presence of 100µM Ryngo 1-23, 
respectively. Similar low level active MMP2 (lanes 5 and 6) was seen in three independent 
experimental repeats, but levels were too low for densitometric analysis. (B) Graph showing 
densitometric analysis of pro-MMP-2 levels under the indicated conditions, expressed 
relative to levels in the control. Bars show the average from three independent experiments. 
**p<0.01, NS = not significant.   
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Figure 6. Ryngo 1-23 does not inhibit clathrin-mediated endocytosis. (A) Quantification of 
labelled transferrin uptake at the indicated concentrations of Ryngo 1-23 in U87MG and B35 
cells. (B) Labelled transferrin uptake following exposure to Dynole 34-2 as indicated. Error 
bars represent SEM of three independent experiments, each performed in triplicate. 
Figure 7. Ryngo 1-23 disrupts the actin cytoskeleton and reduces collagen gel contraction. 
(A) Percentage of spheroid shaped U87MG cells. Micrographs show examples of cells that 
were fixed, permeabilized and stained with fluorescently-labelled phalloidin to detect 
filamentous actin. Arrowheads in control cells indicate actin filaments (stress fibres) in the 
body of the elongated cell and along the cell perimeter. Arrowheads in Ryngo 1-23 indicate 
actin-rich microspikes. (B) Collagen gel contraction assay. Images show examples of gels 
containing U87MG cells released from the wells and then incubated for 5 days. Arrows 
indicate gel diameters. (C) Area of released collagen expressed relative to area of gel in the 
absence of drug. ***p<0.001, one-way ANOVA with Tukey’s post-comparison test. 
Supplementary Movie 1. Brightfield timelapse of B35 cells within 3D collagen gels, under 
control conditions (left panel) or treated with 100 M Ryngo 1-23 (right panel). 
Supplementary Movie 2. Brightfield timelapse of HT1080 cells within 3D collagen gels, 
under control conditions (left panel) or treated with 100 M Ryngo 1-23 (right panel).  
Supplementary Movie 3. Brightfield timelapse of U87MG cells within 3D collagen gels 
(total time 4 hrs and 53 mins).   
Supplementary Movie 4. Brightfield timelapse of U87MG cells within 3D collagen gels 
treated with 100 M Ryngo 1-23 (total time 7 hrs and 24 mins). 
Supplementary Movie 5. Example of rounded U87MG cells treated with 100 M Ryngo 1-
23. 
Supplementary Movie 6. Z-projections of phalloidin stained U87MG cells seeded within 3D 
collagen gels and treated with control media or Ryngo 1-23 as indicated. 
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